Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Akt1 deletion prevents lung tumorigenesis by mutant K-ras.
Hollander MC, Maier CR, Hobbs EA, Ashmore AR, Linnoila RI, Dennis PA. Hollander MC, et al. Among authors: hobbs ea. Oncogene. 2011 Apr 14;30(15):1812-21. doi: 10.1038/onc.2010.556. Epub 2011 Jan 17. Oncogene. 2011. PMID: 21242979 Free PMC article.
Impact of TP53 mutations in Triple Negative Breast Cancer.
Mitri ZI, Abuhadra N, Goodyear SM, Hobbs EA, Kaempf A, Thompson AM, Moulder SL. Mitri ZI, et al. Among authors: hobbs ea. NPJ Precis Oncol. 2022 Sep 9;6(1):64. doi: 10.1038/s41698-022-00303-6. NPJ Precis Oncol. 2022. PMID: 36085319 Free PMC article.
Initial experience in implementing quantitative DCE-MRI to predict breast cancer therapy response in a multi-center and multi-vendor platform setting.
Moloney B, Li X, Hirano M, Saad Eddin A, Lim JY, Biswas D, Kazerouni AS, Tudorica A, Li I, Bryant ML, Wille C, Pyle C, Rahbar H, Hsieh SK, Rice-Stitt TL, Dintzis SM, Bashir A, Hobbs E, Zimmer A, Specht JM, Phadke S, Fleege N, Holmes JH, Partridge SC, Huang W. Moloney B, et al. Front Oncol. 2024 Nov 29;14:1395502. doi: 10.3389/fonc.2024.1395502. eCollection 2024. Front Oncol. 2024. PMID: 39678499 Free PMC article.
Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09).
Hurvitz S, Singh R, Adams B, Taguchi JA, Chan D, Dichmann RA, Castrellon A, Hu E, Berkowitz J, Mani A, DiCarlo B, Callahan R, Smalberg I, Wang X, Meglar I, Martinez D, Hobbs E, Slamon DJ. Hurvitz S, et al. Ther Adv Med Oncol. 2018 Nov 9;10:1758835918807339. doi: 10.1177/1758835918807339. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30542377 Free PMC article.